Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer

Immune checkpoint inhibitors have revolutionized the treatment of selected cancers with meaningful survival improvement in melanoma (1), renal cell carcinoma (2), and non-small cell lung cancer (NSCLC) (3-5). Despite these advances, a substantial proportion of patients do not benefit from treatment.